The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer
Open accessAbstract
Purpose A key research objective in radiation oncology is to identify agents that can improve chemoradiation therapy. Nanoparticle (NP) chemotherapeutics possess several properties, such as preferential accumulation in tumors, that are uniquely suited for chemoradiation therapy. To facilitate the clinical translation of NP chemotherapeutics in chemoradiation therapy, we conducted preclinical evaluation of Genexol-PM, the only clinically approved NP chemotherapeutic with a controlled drug release profile, as a radiosensitizer using non-small cell lung cancer (NSCLC) as a model disease.Methods and materials The physical characteristics and drug release profile of Genexol-PM were characterized. Genexol-PM's efficacy as a radiosensitizer was evaluated in vitro using NSCLC cell lines and in vivo using mouse xenograft models of NSCLC. Paclitaxel dose to normal lung and liver after Genexol-PM administration were quantified and compared with that after Taxol administration.Results Genexol-PM has a size of 23.91 ± 0.41 nm and surface charge of -8.1 ± 3.1 mV. It releases paclitaxel in a controlled release profile. In vitro evaluation of Genexol-PM as a radiosensitizer showed it is an effective radiosensitizer and is more effective than Taxol, its small molecule counterpart, at the half maximal inhibitory concentration. In vivo study of Genexol-PM as a radiosensitizer demonstrated that it is more effective as a radiosensitizer than Taxol. We also found that Genexol-PM leads to lower paclitaxel exposure to normal lung tissue than Taxol at 6 hours postadministration.Conclusions We have demonstrated that Genexol-PM is more effective than Taxol as a radiosensitizer in the preclinical setting and holds high potential for clinical translation. Our data support the clinical evaluation of Genexol-PM in chemoradiation therapy for NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Under sink conditions, paclitaxel was slowly released from the micelle with 65% released at 24 hours and 95% released at 48 hours [110].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [110]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The clinically approved polymeric micelle formulation of paclitaxel Genexol® PM formulation exploits mPEG-b-PDLLA to solubilize paclitaxel and is discussed in greater detail in Section 5.3 [110].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [110]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For instance, micelle systems prepared using PCL-b-PEG-b-PCL displayed high loading up to 28% of paclitaxel [83].”
From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M. H., Pajak, T. F., Weber, R. S., Morrison, W. H., Glisson, B. S., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,161
Analysis of serial measurements in medical research.
Matthews, J. N. S., Altman, D. G., Campbell, M. J., & Royston, P. J. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,137
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J. M., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,685
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic‐Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,774
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,739
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,575
O’Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,131
Fournel, P., Robinet, G., Thomas, P. A., Souquet, P.-J., Léna, H., Vergnenégre, A., Delhoume, J. Y., Treut, J. H. L., Silvani, J.-A., Dansin, É., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.070 · Cited by 543
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 452
Cited by
Sorted by citations
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,113
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine
Simón‐Yarza, T., Mielcarek, A., Couvreur, P., & Serre, C. (2018) · Advanced Materials · doi:10.1002/adma.201707365 · Cited by 661
Polymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 510
A holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Metadata
- Authors
- Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Wang, Andrew Z.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 86
- Issue
- 3
- Pages
- 463-468
- ISSN
- 0360-3016 (ISSN-L)
- PMC
- PMC3750707
- OpenAlex
- W2169498622
- Cited by
- 267
- References
- 22
- Citations by year
- 2026: 20 · 2025: 23 · 2024: 21 · 2023: 31 · 2022: 24 · 2021: 18 · 2020: 23 · 2019: 18 · 2018: 23 · 2017: 19 · 2016: 22 · 2015: 12 · 2014: 8 · 2013: 4
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- International Journal of Radiation Oncology*Biology*Physics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u54ca151652-05, 2k12ca120780-16)
- National Cancer Institute (5-K12-CA120780-01-05, U54‐CA151652, 1-U54-CA151652-01, K12-CA120780, R01CA178748)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- paclitaxel, nanoparticle drug delivery, radiosensitizers, non-small cell lung cancer, chemoradiotherapy, controlled drug release, nanoparticle size and surface charge, taxol comparison
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Carcinoma, Non-Small-Cell Lung, Lung, Lung Neoplasms, Mice, Nude, Polymers, Radiation-Sensitizing Agents, Paclitaxel, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Mice, Nanoparticles, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
